SCHEMBL1543531

SCHEMBL1543531

N#CCc1cccnc1C#N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.53
MPO P05164 1/20 0.40
HSD11B1 P28845 3/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
PLCG1 P19174 1/20 0.37
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LRRK2 Q5S007 1/20 0.33
KDM4E B2RXH2 1/20 0.33
KDM4D Q6B0I6 1/20 0.33
ALOX15 P16050 1/20 0.32
ELANE P08246 1/20 0.32
LMNA P02545 1/20 0.32
PKM P14618 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748563 1.00 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1HPGD
SCHEMBL3620497 0.91 CYP11B1 (0.47) CYP11B1MPOHSD11B1ALDH1A1HPGD
SCHEMBL12490223 0.81 CYP11B1 (0.50) CYP11B1MPOHSD11B1ALDH1A1PLCG1
SCHEMBL1007086 0.80 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1PLCG1
SCHEMBL6109965 0.80 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1HPGD
SCHEMBL25347053 0.80 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1PLCG1
SCHEMBL129267 0.80 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1PLCG1
SCHEMBL929481 0.80 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1HPGD
SCHEMBL1007759 0.80 CYP11B1 (0.53) CYP11B1MPOHSD11B1ALDH1A1PLCG1
Hydrochloric Acid SCHEMBL26104353 0.78 CYP11B1 (0.51) CYP11B1MPOHSD11B1ALDH1A1PLCG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-12570671-B2 Substituted oxoisoindoline compounds for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2026-03-10 US disclosed
EP-4126843-B1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2026-02-11 EP disclosed
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-04-03 US disclosed
EP-4524135-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-03-19 EP disclosed
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2025-02-27 US disclosed
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2025-01-21 US disclosed
CN-119212988-A Kinesin KIF18A inhibitor and application thereof 上海湃隆生物科技有限公司 2024-12-27 CN disclosed
CN-115605466-B Substituted oxoisoindoline compounds for the treatment of cancer 百时美施贵宝公司 2024-11-01 CN disclosed
EP-4444420-A2 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
US-20020045628-A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-18 US disclosed
CN-1336916-A Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression AMERICAN HOME PROD (US) 2002-02-20 CN disclosed
US-6313126-B1 FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY AMERICAN HOME PRODUCTS CORP 2001-11-06 US disclosed
EP-1147083-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2001-10-24 EP disclosed
US-6136821-A ANTIINFLAMMATORY AGENTS, ANTIHISTAMINES AND BRONCHODILATOR AGENTS NOVARTIS AG (CH) 2000-10-24 US disclosed
WO-2000040554-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2000-07-13 WO disclosed
EP-0934320-A1 NAPHTHYRIDINE DERIVATIVES Novartis AG (CH) 1999-08-11 EP disclosed
WO-1998018796-A1 NAPHTHYRIDINE DERIVATIVES NOVARTIS AG (CH) 1998-05-07 WO disclosed
US-4801590-A ANGINA, ANTICANCER, CARDIOVASCULAR DISORDERS, HEADACHES, PSORIASIS, ASTHMA, ANTICOAGULANTS BEIERSDORF AG (DE) 1989-01-31 US disclosed
EP-0253171-A1 Pyrido[1,8]naphthyridinones, process for their preparation and their use and compositions containing them Beiersdorf-Lilly GmbH (DE) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI CYP11B1 567/4885MPO 2248/4885HSD11B1 2671/4885
US-20020045628-A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression HTR2C, TPH1, TPH2 CYP11B1 388/4885MPO 598/4885HSD11B1 1060/4885
US-12570671-B2 Substituted oxoisoindoline compounds for the treatment of cancer NR3C1, NR2C2, RIOX2 CYP11B1 785/4885MPO 3264/4885HSD11B1 1388/4885
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DYRK2, DYRK1A, PYGB CYP11B1 1089/4885MPO 3913/4885HSD11B1 2360/4885
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI CYP11B1 567/4885MPO 2248/4885HSD11B1 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.